OpenAlex
PricingAboutJobs
Log inGet started
Work

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, in subjects with renal impairment

HTML

Year: 2013
Type: article
Study design: Clinical Trial
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12182
Authors: S. Macha, M. Mattheus, A. Halabi, S. Pinnetti, H. J. Woerle, U. C. Broedl
Institutions: Boehringer Ingelheim (United States), Boehringer Ingelheim (Germany), Clinical Research Services
Language: English

Topic: Diabetes Treatment and Management
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: empagliflozin, SGLT2 inhibitors, renal dysfunction, pharmacokinetics, pharmacodynamics, renal clearance, urinary glucose excretion, estimated glomerular filtration rate, end-stage renal disease, type 2 diabetes, drug safety, dose adjustment
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W1994679938
FWCI: 7.427
Cites: 12
Cited by: 126
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security